Azithromycin (Zithromax)

Azithromycin is a macrolide antibiotic belonging to the azalide subclass, distinguished by its unique chemical structure that includes a nitrogen atom in the lactone ring. This structural modification provides azithromycin with exceptional tissue penetration, an extended half-life, and improved stability in acidic environments compared to earlier macrolide antibiotics. In reptile medicine, azithromycin has become an increasingly valuable therapeutic option due to its broad spectrum of activity against gram-positive bacteria, certain gram-negative organisms, and intracellular pathogens including Chlamydia and Mycoplasma species. The medication works by binding to the 50S ribosomal subunit of susceptible bacteria, effectively inhibiting protein synthesis and preventing bacterial replication.

The development of azithromycin in the 1980s represented a significant advancement in macrolide antibiotic therapy, and its application in veterinary medicine, including reptile care, followed as practitioners recognized its favorable pharmacokinetic properties. Unlike many antibiotics that require frequent dosing, azithromycin concentrates extensively in tissues and maintains therapeutic levels for extended periods, making it particularly suitable for reptile patients where frequent handling and medication administration can cause significant stress. The medication's ability to accumulate within phagocytes and be transported directly to sites of infection enhances its effectiveness against intracellular pathogens that commonly affect reptilian species.

Azithromycin is available in several formulations suitable for reptile use, including oral suspensions, tablets that can be compounded into appropriate concentrations, and injectable solutions for cases requiring parenteral administration. The oral suspension is often preferred for reptile patients due to ease of administration via stomach tube or mixing with food items, though the injectable form may be necessary for severely ill patients or those unable to tolerate oral medication. Compounding pharmacies play an essential role in preparing azithromycin at concentrations appropriate for the wide range of reptile body sizes, from small geckos weighing just a few grams to large iguanas and monitor lizards.

Overall effectiveness of azithromycin in reptile patients is considered good when used appropriately for susceptible infections, particularly respiratory conditions and chlamydial diseases. The medication's extended dosing intervals reduce handling stress, and its broad tissue distribution ensures adequate drug concentrations reach infected sites. However, as with all reptile medications, efficacy is influenced by maintaining the patient at appropriate temperatures within their preferred optimum temperature zone, and treatment success depends on accurate diagnosis by a reptile-experienced veterinarian who can determine whether azithromycin is the most appropriate antibiotic choice for the specific infection being treated.

Azithromycin serves as a primary therapeutic agent for treating respiratory infections in reptiles, which represent one of the most common presenting complaints in herpetological medicine. Upper and lower respiratory tract infections caused by susceptible gram-positive bacteria respond well to azithromycin therapy, and the medication's excellent penetration into respiratory tissues makes it particularly effective for pneumonia and related conditions. The drug is especially valuable for treating infections caused by intracellular pathogens such as Chlamydia and Mycoplasma species, organisms that are notoriously difficult to eliminate with many other antibiotic classes due to their protected intracellular location.

In lizard species, azithromycin finds frequent application for treating respiratory infections in bearded dragons, one of the most commonly kept pet reptiles that frequently presents with respiratory disease. Bearded dragons with early signs of respiratory infection, including mucus discharge, open-mouth breathing, or decreased appetite, may benefit from azithromycin therapy when bacterial culture and sensitivity testing indicate susceptibility. Leopard geckos, chameleons, and other commonly kept lizard species also receive azithromycin for similar respiratory conditions, though the inherent sensitivity of chameleons requires particularly careful monitoring during treatment. Larger lizard species including iguanas and monitor lizards may be prescribed azithromycin for respiratory infections, skin and soft tissue infections caused by susceptible organisms, and other bacterial conditions where the medication's spectrum of activity is appropriate.

Chelonian species including turtles and tortoises represent another important patient population for azithromycin therapy. Upper respiratory tract disease in tortoises, often associated with Mycoplasma agassizii and related organisms, has been treated with azithromycin with variable success. Box turtles, desert tortoises, and other chelonian species suffering from chronic respiratory disease may receive extended courses of azithromycin as part of comprehensive treatment protocols. Aquatic turtles with respiratory infections can also benefit from azithromycin therapy, though maintaining appropriate water quality during treatment remains essential for recovery.

Beyond respiratory applications, azithromycin is indicated for treating various soft tissue infections, certain skin conditions caused by susceptible bacteria, and systemic infections where gram-positive organisms or intracellular pathogens are implicated. The medication may be used for treating infectious stomatitis (mouth rot) in conjunction with local wound care, particularly when culture results suggest susceptibility to macrolide antibiotics. Azithromycin can also serve as part of treatment protocols for septicemia when the causative organism falls within its spectrum of activity, though more severe systemic infections often require broader-spectrum antibiotics or combination therapy.

Veterinarians typically choose azithromycin when culture and sensitivity results indicate susceptibility, when intracellular pathogens are suspected or confirmed, when extended dosing intervals would benefit the patient by reducing handling stress, or when oral administration is preferred over injectable routes. The medication is particularly valuable in situations where client compliance may be challenging, as the extended dosing schedule improves the likelihood of completing the full treatment course. Azithromycin may also be selected when other antibiotic options have failed or when the patient has experienced adverse reactions to alternative medications.

Dosing of azithromycin in reptile patients must be determined exclusively by a veterinarian experienced in reptile medicine, as numerous factors influence appropriate dosing including species, body weight, infection severity, and individual patient considerations. No specific numeric doses should be administered without direct veterinary guidance, as reptile pharmacokinetics differ substantially from mammalian patients, and inappropriate dosing can result in treatment failure or toxicity. The veterinarian will calculate the appropriate dose based on current research, clinical experience, and the specific circumstances of each case, often utilizing pharmacokinetic data extrapolated from studies in various reptile species.

Temperature considerations play a critical role in azithromycin dosing and efficacy in reptile patients, as drug metabolism is directly dependent on body temperature. Reptiles maintained below their preferred optimum temperature zone will metabolize medications more slowly, potentially leading to drug accumulation and increased toxicity risk. Conversely, inadequate temperatures may result in subtherapeutic drug activity as the immune system functions suboptimally in cold reptiles. Before initiating azithromycin therapy, reptile keepers must ensure the patient's enclosure provides appropriate temperature gradients, and maintaining proper thermal conditions throughout the treatment course is essential for consistent drug metabolism and optimal therapeutic outcomes.

Azithromycin administration in reptiles typically occurs via the oral route using suspensions delivered directly into the mouth or through stomach tube placement for patients requiring more precise dosing or those unwilling to accept oral medication. The oral suspension can sometimes be mixed with favored food items for voluntary consumption, though this method may result in incomplete dosing if the reptile does not consume the entire medicated portion. Injectable azithromycin may be administered intramuscularly in cases where oral administration is not feasible, with strict adherence to anterior body injection sites being absolutely essential. All intramuscular injections must be placed in the forelimbs, shoulder muscles, or anterior epaxial muscles, never in the hindlimbs, tail, or posterior half of the body due to the reptilian renal portal system.

Dosing frequency for azithromycin in reptiles typically involves extended intervals compared to mammalian patients, with administration often occurring every 24 to 72 hours or even less frequently depending on the formulation and treatment protocol established by the veterinarian. The extended half-life of azithromycin allows for these prolonged dosing intervals, which beneficially reduces handling stress for reptile patients. Treatment duration varies based on the infection being treated, clinical response, and veterinary assessment, with courses typically extending from one to several weeks. The veterinarian may adjust dosing intervals based on clinical response and may recommend follow-up examinations to assess treatment progress.

Species-specific administration considerations include recognizing that smaller reptile species such as leopard geckos and juvenile bearded dragons require precisely compounded formulations to allow accurate dosing of tiny volumes. Chameleons and other particularly sensitive species may require conservative dosing approaches with careful monitoring for adverse effects. Larger species including adult iguanas, tegus, and monitor lizards may tolerate standard formulations more readily, though accurate body weight measurement remains essential for appropriate dose calculation. Chelonians present unique administration challenges due to their ability to withdraw into their shells, often requiring gentle restraint techniques or patience while waiting for the animal to extend its head for oral medication.

Owners administering azithromycin at home must receive thorough instruction from the veterinary team regarding proper medication handling, accurate volume measurement using appropriate syringes, and safe restraint techniques for their specific reptile species. Oral administration typically involves gently opening the reptile's mouth, directing the syringe toward the back of the throat while avoiding the tracheal opening, and slowly dispensing the medication to allow swallowing. Owners should observe for signs of aspiration including immediate distress, coughing, or bubbling from the nostrils. Medication should be stored according to label directions, and any missed doses should be discussed with the veterinarian rather than doubling subsequent doses. Completing the full prescribed course is essential even if the reptile appears improved, as premature discontinuation promotes antibiotic resistance.

Azithromycin is generally well-tolerated in reptile patients when administered at appropriate doses under veterinary supervision, though several potential side effects warrant monitoring throughout the treatment course. Gastrointestinal disturbances represent the most commonly observed adverse effects, potentially manifesting as decreased appetite, regurgitation, or changes in fecal consistency. Reptiles receiving oral azithromycin may exhibit temporary reluctance to feed, which can be particularly concerning in species that are already anorexic due to illness. Monitoring food intake and body weight during treatment helps identify patients experiencing significant gastrointestinal upset requiring veterinary reassessment.

Temperature-related effects significantly influence how reptile patients respond to azithromycin therapy and the likelihood of experiencing adverse reactions. Reptiles maintained at suboptimal temperatures may accumulate the medication due to slowed metabolism, potentially reaching concentrations that cause toxicity even at otherwise appropriate doses. Signs of drug accumulation may include pronounced lethargy, complete anorexia, neurological changes, or other signs of systemic illness that exceed what would be expected from the underlying infection alone. Ensuring consistent maintenance at species-appropriate temperatures throughout treatment minimizes the risk of temperature-related adverse effects and supports optimal drug clearance.

While azithromycin is considered less nephrotoxic than aminoglycoside antibiotics, monitoring for any signs of renal compromise remains prudent, particularly in patients with pre-existing kidney disease or those receiving concurrent medications that affect renal function. Reptiles with compromised kidney function may not clear azithromycin efficiently, increasing the risk of accumulation and adverse effects. Signs potentially indicating renal stress include changes in urate appearance, decreased urination in aquatic species, general malaise, or failure to respond appropriately to treatment. Maintaining adequate hydration throughout the treatment course supports renal function and drug clearance.

Species-specific adverse reactions have been noted in various reptile groups, though comprehensive documentation remains limited due to the extra-label nature of azithromycin use in these species. Chameleons and other particularly sensitive species may exhibit more pronounced side effects at doses tolerated by hardier species, necessitating conservative dosing approaches and vigilant monitoring. Some individual reptiles may demonstrate idiosyncratic reactions not commonly reported in the literature, emphasizing the importance of close observation during initial doses. Injection site reactions including local swelling, discoloration, or apparent discomfort may occur with intramuscular administration, though these are generally less severe than reactions associated with some other injectable antibiotics.

Owners should contact their reptile veterinarian promptly if any concerning signs develop during azithromycin treatment, including complete refusal of food for extended periods, persistent regurgitation, unusual lethargy or weakness beyond what would be expected from the illness, neurological signs such as tremors or incoordination, changes in breathing patterns, or any other sudden changes in condition. The veterinarian may recommend adjusting the dose, extending the dosing interval, temporarily discontinuing treatment, or switching to an alternative antibiotic depending on the nature and severity of observed side effects. Early recognition and reporting of adverse effects allows for timely intervention and treatment modification to ensure patient safety while still addressing the underlying infection.

Azithromycin should not be administered to reptiles with documented hypersensitivity to macrolide or azalide antibiotics, as allergic reactions can potentially be severe and life-threatening. While true allergic reactions to azithromycin are uncommonly documented in reptile patients, any history of adverse reactions to erythromycin, clarithromycin, or other macrolide antibiotics should be communicated to the veterinarian before treatment initiation. Patients that have previously experienced severe gastrointestinal disturbances, respiratory distress, or other serious adverse effects following macrolide administration should generally receive alternative antibiotic therapy.

Certain medical conditions constitute relative or absolute contraindications for azithromycin therapy in reptiles. Patients with significant hepatic impairment may not metabolize azithromycin efficiently, potentially leading to drug accumulation and increased toxicity risk. Reptiles with known liver disease, those exhibiting signs of hepatic dysfunction, or those with concurrent conditions affecting liver function should receive azithromycin only with careful consideration of risks and benefits. Similarly, while azithromycin is considered less nephrotoxic than some alternatives, reptiles with significant renal disease may experience delayed drug clearance and require dose adjustments or selection of alternative antibiotics. Severely dehydrated reptiles should have fluid status corrected before initiating antibiotic therapy to support appropriate drug distribution and clearance.

Temperature and husbandry contraindications represent critical considerations specific to reptile patients. Azithromycin therapy should not be initiated in reptiles that cannot be maintained at appropriate temperatures, as the unpredictable pharmacokinetics in hypothermic patients create substantial risks of treatment failure or toxicity. Reptiles housed in inappropriate enclosures lacking proper temperature gradients, those with non-functional heating equipment, or those in environments where consistent temperature maintenance is not possible should have husbandry issues corrected before beginning treatment. Additionally, severely debilitated reptiles may require supportive care including thermal support, fluid therapy, and nutritional support before antibiotic therapy can be safely administered.

Azithromycin should not be used when bacterial culture and sensitivity testing indicates resistance to macrolide antibiotics, as treatment would be ineffective and could contribute to further resistance development. The medication should not be relied upon for infections caused by gram-negative bacteria outside its spectrum of activity, as many clinically significant reptile pathogens including Pseudomonas, Aeromonas, and Salmonella species are inherently resistant to macrolide antibiotics. Anaerobic bacterial infections may not respond adequately to azithromycin monotherapy and often require alternative or combination antibiotic approaches. When empirical therapy is necessary before culture results are available, the veterinarian will consider the most likely pathogens and whether azithromycin provides appropriate coverage for the suspected infection.

Concurrent administration of azithromycin with other potentially nephrotoxic medications warrants careful consideration and veterinary oversight, even though azithromycin itself carries relatively low nephrotoxicity risk. Combination therapy with aminoglycoside antibiotics such as amikacin or gentamicin should be approached cautiously, with particular attention to patient hydration status and renal function monitoring. While this combination may sometimes be necessary for treating resistant infections or polymicrobial disease, the veterinarian will weigh the benefits against potential risks and implement appropriate monitoring protocols. Other medications with nephrotoxic potential including certain antifungal agents should similarly be combined with azithromycin only when clearly indicated and with appropriate monitoring.

Several drug interactions may affect azithromycin efficacy or alter the effects of concurrently administered medications. Antacids containing aluminum or magnesium may reduce azithromycin absorption if administered simultaneously, though separating administration times typically prevents this interaction. Medications that significantly alter gastrointestinal motility may affect azithromycin absorption from the digestive tract. The veterinarian will consider the timing of various medication administrations to minimize potential interactions while ensuring therapeutic levels of all necessary drugs. Azithromycin may interact with certain cardiac medications, though the clinical significance in reptile patients is not well established.

Interactions with supplements commonly administered to reptile patients deserve consideration during azithromycin therapy. Calcium supplementation, essential for many reptile species particularly those at risk for metabolic bone disease, can generally be continued during treatment though administration timing relative to oral azithromycin may be adjusted to minimize potential absorption interference. Vitamin and mineral supplements should be continued as nutritionally indicated, with the veterinarian providing guidance on any necessary timing adjustments. Probiotic supplements intended to support gastrointestinal health may be beneficial during antibiotic therapy, though they should be administered separately from the antibiotic dose to prevent interference with beneficial organism viability.

Certain medication combinations are generally considered safe with azithromycin and may be prescribed concurrently when treating complex cases. Supportive care medications including appetite stimulants, anti-nausea medications, and fluid therapy components typically do not interact significantly with azithromycin. The veterinarian may prescribe concurrent anti-inflammatory medications when inflammation contributes to the disease process, selecting agents that complement rather than interfere with antibiotic therapy. Topical medications for wound care, ophthalmic preparations, and other locally applied treatments generally pose no interaction concerns with systemic azithromycin therapy. Complete disclosure of all medications, supplements, and treatments the reptile is receiving enables the veterinarian to identify potential interactions and develop a safe, effective therapeutic plan.

Temperature maintenance throughout azithromycin treatment represents perhaps the most critical precaution for reptile patients, directly influencing drug metabolism, therapeutic efficacy, and toxicity risk. Before initiating therapy, verify that the enclosure provides appropriate temperature gradients with both a warm basking area and a cooler retreat, allowing the reptile to thermoregulate effectively. The basking zone should reach species-appropriate temperatures while the cool end remains within the acceptable range for that species. Sick reptiles often benefit from temperatures at the higher end of their normal range to support immune function, though extreme temperatures should be avoided. Monitor temperatures daily using reliable thermometers, and address any heating equipment malfunctions immediately to prevent treatment complications.

Injection site warnings demand strict adherence when administering intramuscular azithromycin to reptile patients. All intramuscular injections must be placed in the anterior portion of the body, specifically the forelimbs, shoulder musculature, or front half of the epaxial muscles along the spine. Never inject into the hindlimbs, tail, or posterior body region due to the reptilian renal portal system, which directs blood from the caudal body through the kidneys before reaching systemic circulation. Injecting in posterior locations may result in reduced drug efficacy as the medication is filtered or excreted before reaching therapeutic concentrations, and with any nephrotoxic medication, posterior injection increases the risk of kidney damage. This anatomical consideration applies to all reptile species regardless of size or body configuration.

Hydration requirements during azithromycin therapy support appropriate drug distribution and clearance while maintaining overall patient health. Reptiles should have constant access to fresh water appropriate to their species, whether provided in a water dish, through regular soaking, or through environmental humidity. Dehydrated reptiles should receive fluid therapy to correct deficits before starting antibiotic treatment, and hydration status should be monitored throughout the treatment course. Signs of dehydration in reptiles include sunken eyes, decreased skin elasticity, tacky mucous membranes, and concentrated urates. Maintaining appropriate humidity levels in the enclosure, particularly for tropical species, supports respiratory health and overall hydration status.

Monitoring requirements during azithromycin treatment include regular assessment of clinical signs, appetite, activity level, and treatment response. Owners should maintain daily observations noting any changes in behavior, feeding, defecation, or respiratory effort. The veterinarian may recommend follow-up examinations to assess response to therapy, particularly for serious infections or cases where initial response is uncertain. Reptiles with respiratory infections should be monitored for improvement in breathing patterns, decreased mucus discharge, and increased activity levels. Failure to improve within an expected timeframe warrants veterinary reassessment and potential modification of the treatment plan.

Human safety considerations when handling azithromycin and administering medication to reptiles include basic hygiene practices to prevent accidental drug exposure and zoonotic disease transmission. Wash hands thoroughly before and after handling medication and reptile patients. Avoid touching eyes or mouth after handling medications or reptiles until hands have been washed. Individuals with known allergies to macrolide antibiotics should take extra precautions or have another household member administer the medication. Proper restraint techniques prevent injury to both the handler and the reptile patient, and seeking guidance from the veterinary team on safe handling methods for specific species helps ensure medication administration occurs without incident.

Azithromycin storage requirements vary depending on the specific formulation prescribed by the veterinarian, and following label directions precisely ensures medication stability and efficacy throughout the treatment course. Tablets and capsules typically require storage at controlled room temperature away from excessive heat, light, and moisture, with the original container often providing appropriate protection. Oral suspensions may require refrigeration after reconstitution, though some formulations remain stable at room temperature; the dispensing pharmacy will provide specific instructions for the prescribed product. Injectable formulations have particular storage requirements that must be followed to maintain sterility and potency, and multi-dose vials require careful handling to prevent contamination.

Stability and shelf life considerations affect how long reconstituted suspensions remain safe and effective for use. Oral suspensions prepared by compounding pharmacies will have designated beyond-use dates that should be strictly observed, as potency may decrease and bacterial contamination risk increases beyond this timeframe. Unused medication remaining after completing the prescribed course should generally be disposed of properly rather than saved for potential future use, as subsequent treatment requires fresh veterinary assessment and potentially different therapeutic approaches. The veterinarian or pharmacist can provide guidance on appropriate disposal methods for unused medications to prevent environmental contamination and accidental exposure.

Safe handling and disposal practices protect household members, other animals, and the environment from unintended medication exposure. Keep azithromycin in its original labeled container out of reach of children and pets, stored separately from human medications to prevent confusion. When administering oral medication, avoid creating aerosols that could be inhaled, and clean any spilled medication promptly. Use appropriate personal protective equipment if handling injectable formulations extensively. Dispose of expired or unused medication through veterinary take-back programs, pharmacy disposal programs, or following specific disposal instructions provided by the dispensing pharmacy. Never dispose of medications by flushing down drains or toilets unless specifically directed, as this can contribute to environmental antibiotic contamination and resistance development. Syringes and other administration supplies should be disposed of according to local regulations for medical waste.

Lizard species represent a major patient population for azithromycin therapy, with bearded dragons being among the most frequently treated due to their popularity and susceptibility to respiratory infections. Bearded dragons receiving azithromycin should be maintained at appropriate basking temperatures, and their relatively tractable nature generally facilitates oral medication administration. Leopard geckos and other small gecko species require precisely compounded formulations to deliver accurate doses given their small body size, and careful handling during administration prevents injury to these delicate animals. Chameleons are notably sensitive to medications and stress, warranting conservative dosing approaches, minimal handling, and vigilant monitoring for adverse effects. Larger lizard species including green iguanas, tegus, and monitor lizards can generally tolerate azithromycin well, though their size and potential defensive behaviors require appropriate restraint techniques for safe medication administration.

Chelonian patients including turtles and tortoises present unique considerations for azithromycin therapy. Tortoises with upper respiratory tract disease, a common indication for macrolide antibiotic therapy, often require extended treatment courses and may show slow clinical improvement. The ability of chelonians to withdraw into their shells can complicate oral medication administration, requiring patience and gentle technique to access the head when extended. Aquatic turtle species receiving azithromycin must be maintained in clean water to support recovery, and some practitioners recommend removing affected turtles from water briefly after oral dosing to reduce immediate regurgitation risk. Box turtles and other semi-aquatic species should have both water access and dry areas during treatment, with medication administration timed to maximize retention and absorption.

Temperature requirements vary among reptile species and must be maintained within appropriate ranges throughout azithromycin treatment for optimal drug metabolism. Desert species including bearded dragons, leopard geckos, and desert tortoises require higher basking temperatures compared to temperate or tropical species. Tropical species including many chameleons, green iguanas, and various turtle species need moderate temperatures with higher humidity. Temperature gradients allowing behavioral thermoregulation remain essential regardless of species, enabling the reptile to select optimal body temperatures as needed. Species-specific temperature requirements should be researched and implemented before initiating antibiotic therapy, with veterinary guidance for appropriate temperature adjustments in sick animals.

Size considerations significantly influence azithromycin dosing and administration across the vast range of reptile body sizes seen in clinical practice. Small species weighing just a few grams require highly dilute compounded formulations and tiny administration volumes, demanding precise measurement using appropriate syringes. Medium-sized reptiles may receive standard compounded preparations with volumes that are more easily measured and administered. Large reptiles including adult iguanas, large tortoises, and monitor lizards require proportionally larger doses that may be administered using standard formulations or larger-volume compounded preparations. Regardless of size, accurate body weight measurement is essential for appropriate dose calculation, and weights should be rechecked periodically during extended treatment courses to adjust dosing as needed.

Alternative macrolide antibiotics within the same drug class provide options when azithromycin is unavailable or contraindicated for a particular patient. Clarithromycin offers similar spectrum coverage with some pharmacokinetic differences that may be advantageous in specific situations, though it typically requires more frequent dosing than azithromycin. Erythromycin, the prototype macrolide antibiotic, remains available for reptile use though its gastrointestinal side effects may be more pronounced than newer macrolides. Tylosin, another macrolide antibiotic sometimes used in reptile medicine, may provide alternative coverage for certain infections. The veterinarian will select among available macrolide options based on the specific infection, patient factors, and available formulations.

Different antibiotic classes may be more appropriate than macrolides for many reptile infections, particularly those caused by gram-negative bacteria that predominate in reptile bacterial disease. Fluoroquinolone antibiotics including enrofloxacin and marbofloxacin provide broad gram-negative coverage commonly needed for reptile infections, though administration considerations differ from macrolides. Beta-lactam antibiotics such as ceftazidime offer another option for gram-negative infections without the nephrotoxicity concerns associated with aminoglycosides. Aminoglycoside antibiotics including amikacin remain important for serious gram-negative infections despite their nephrotoxic potential, requiring careful monitoring and strict anterior injection site adherence. Metronidazole addresses anaerobic bacterial infections and certain protozoal parasites not covered by macrolide antibiotics.

Combination therapy approaches may be implemented when single-agent treatment is insufficient or when polymicrobial infections require broader coverage. Azithromycin may be combined with antibiotics providing gram-negative coverage when mixed infections are documented or suspected based on clinical presentation. The veterinarian will determine appropriate combinations based on culture results, clinical judgment, and consideration of potential drug interactions and cumulative adverse effect risks. Sequential therapy using different antibiotic classes may be employed for resistant infections or those showing incomplete response to initial treatment. All combination and sequential therapy decisions should be made by the reptile veterinarian based on individual patient assessment and diagnostic findings.